Overview
IASLC’s Education Committee presents a one-hour webinar offering a concise and comprehensive overview of the most significant studies and emerging data on thoracic malignancies presented at the 2025 ESMO (European Society for Medical Oncology) Congress. Expert faculty will highlight key clinical findings, discuss their implications for practice, and provide context on how the latest research may shape the future of lung cancer care worldwide.
- Identify and interpret key clinical studies on thoracic malignancies presented at the 2025 ESMO Congress.
- Describe emerging advancements in the diagnosis and treatment of thoracic tumors.
- Apply evidence-based findings from the 2025 ESMO Congress to enhance patient care plans.
- Phase III Study of Ivonescimab plus chemotherapy versus Tislelizumab plus chemotherapy as First-line Treatment for advanced squamous non-small cell lung cancer (HARMONi-6) - Shun Lu (Shanghai, China)
- Sacituzumab tirumotecan (sac-TMT) vs platinum-based chemotherapy in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs: results from the randomized, multi-center phase 3 OptiTROP-Lung04 study - Li Zhang
- Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: interim analysis (IA) of the phase 2 MDT-BRIDGE study - M. Reck
- Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study - Presenter. M. Wermke.
The IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
IASLC designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Identify and interpret key clinical studies on thoracic malignancies presented at the 2025 ESMO Congress.
- Describe emerging advancements in the diagnosis and treatment of thoracic tumors.
- Apply evidence-based findings from the 2025 ESMO Congress to enhance patient care plans.
- Phase III Study of Ivonescimab plus chemotherapy versus Tislelizumab plus chemotherapy as First-line Treatment for advanced squamous non-small cell lung cancer (HARMONi-6) - Shun Lu (Shanghai, China)
- Sacituzumab tirumotecan (sac-TMT) vs platinum-based chemotherapy in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs: results from the randomized, multi-center phase 3 OptiTROP-Lung04 study - Li Zhang
- Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: interim analysis (IA) of the phase 2 MDT-BRIDGE study - M. Reck
- Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study - Presenter. M. Wermke.
The IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
IASLC designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Share
Participants
Francesco Passiglia
MD, PhD
Associate Professor, Medical Oncology
University of Turin
Luis Raez
MD, FACP, FCCP
Medical Director, Chief Scientific Officer
Memorial Cancer Institute (MCI)
Oncology Research Director of Memorial Health Care System (MHS)
Pilar Garrido
MD
Head of the Thoracic Tumours Section
University Hospital Ramón y Cajal
Associate Professor of Medical Oncology at Universidad de Alcalá
Shun Lu
MD.
Chief
Shanghai Chest Hospital
Shanghai Lung Cancer Center
Professor at Shanghai Jiaotong University
Executive Board Member of the Chinese Society of Clinical Oncology
Past Chair of Chinese Lung Cancer Association
Martin Reck
MD
Head of Department of Thoracic Oncology
LungenClinic - Grosshansdorf (Germany)
Martin Wermke
MD
Professor for Experimental Cancer Therapy
The National Center for Tumor Diseases Dresden